Allison W Kurian

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Occurrence of breast cancer subtypes in adolescent and young adult women
    Theresa H M Keegan
    Cancer Prevention Institute of California, 2201 Walnut Ave, Suite 300, Fremont, CA 94538, USA
    Breast Cancer Res 14:R55. 2012
  2. ncbi A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Allison W Kurian
    Department of Medicine, Division of Oncology, and the Veterans Affairs Palo Alto Health Care System and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA
    J Clin Oncol 25:634-41. 2007
  3. pmc Performance of BRCA1/2 mutation prediction models in Asian Americans
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    J Clin Oncol 26:4752-8. 2008
  4. pmc Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    Breast Cancer Res 12:R99. 2010
  5. doi BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications
    Allison W Kurian
    Department of Medicine and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    Curr Opin Obstet Gynecol 22:72-8. 2010
  6. pmc Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage
    Allison W Kurian
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5820, USA
    Health Expect 8:221-33. 2005
  7. ncbi Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk
    Allison W Kurian
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820
    Cancer Epidemiol Biomarkers Prev 14:1082-9. 2005
  8. pmc Online tool to guide decisions for BRCA1/2 mutation carriers
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 30:497-506. 2012
  9. ncbi Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
    Anne Renee Hartman
    Department of Medicine, Stanford University School of Medicine, Stanford, California 94305 5458, USA
    Cancer 100:479-89. 2004
  10. pmc Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers
    Allison W Kurian
    Departments of Medicine, Health Research and Policy, and Radiology, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 28:222-31. 2010

Detail Information

Publications45

  1. pmc Occurrence of breast cancer subtypes in adolescent and young adult women
    Theresa H M Keegan
    Cancer Prevention Institute of California, 2201 Walnut Ave, Suite 300, Fremont, CA 94538, USA
    Breast Cancer Res 14:R55. 2012
    ....
  2. ncbi A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer
    Allison W Kurian
    Department of Medicine, Division of Oncology, and the Veterans Affairs Palo Alto Health Care System and Center for Primary Care and Outcomes Research, Stanford University, Stanford, CA, USA
    J Clin Oncol 25:634-41. 2007
    ..We sought to evaluate the cost effectiveness of these regimens, which are expensive and potentially toxic...
  3. pmc Performance of BRCA1/2 mutation prediction models in Asian Americans
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    J Clin Oncol 26:4752-8. 2008
    ..We compared the performance in Asian and white individuals of two widely used BRCA1/2 mutation prediction models, BRCAPRO and Myriad II...
  4. pmc Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    Breast Cancer Res 12:R99. 2010
    ....
  5. doi BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications
    Allison W Kurian
    Department of Medicine and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    Curr Opin Obstet Gynecol 22:72-8. 2010
    ..To summarize evidence on the prevalence and spectrum of BRCA1 and BRCA2 BRCA1/2 mutations across racial and ethnic groups and discuss implications for clinical practice...
  6. pmc Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage
    Allison W Kurian
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305 5820, USA
    Health Expect 8:221-33. 2005
    ....
  7. ncbi Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk
    Allison W Kurian
    Division of Oncology, Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820
    Cancer Epidemiol Biomarkers Prev 14:1082-9. 2005
    ..Most publications on ductal lavage for cell collection report cannulating fluid-yielding ducts only. We report lavage of fluid-yielding and non-fluid-yielding ducts in women at high inherited breast cancer risk...
  8. pmc Online tool to guide decisions for BRCA1/2 mutation carriers
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 30:497-506. 2012
    ..A clinical decision tool could guide these complex choices...
  9. ncbi Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
    Anne Renee Hartman
    Department of Medicine, Stanford University School of Medicine, Stanford, California 94305 5458, USA
    Cancer 100:479-89. 2004
    ....
  10. pmc Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers
    Allison W Kurian
    Departments of Medicine, Health Research and Policy, and Radiology, Stanford University School of Medicine, Stanford, CA, USA
    J Clin Oncol 28:222-31. 2010
    ..We used decision analysis to simulate risk-reducing strategies in BRCA1/2 mutation carriers and to compare resulting survival probability and causes of death...
  11. pmc Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment
    Allison W Kurian
    Allison W Kurian, Meredith A Mills, Kerry E Kingham, Lisa McPherson, Alice S Whittemore, Valerie McGuire, Uri Ladabaum, James M Ford, Stanford University School of Medicine, Stanford Emily E Hare, Yuya Kobayashi, Stephen E Lincoln, Michele Cargill, InVitae, San Francisco, CA
    J Clin Oncol 32:2001-9. 2014
    ..Multiple-gene sequencing is entering practice, but its clinical value is unknown. We evaluated the performance of a customized germline-DNA sequencing panel for cancer-risk assessment in a representative clinical sample...
  12. pmc Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers
    Elizabeth A Schackmann
    Departments of Medicine and of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305 5405, USA
    Fam Cancer 12:65-73. 2013
    ..50 and 4.69, on a 1-5 scale). Patients and health care providers rated the decision tool highly on measures of usability and clinical relevance. These results will guide a larger study of the tool's impact on clinical decisions...
  13. ncbi Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging
    Sylvia K Plevritis
    Department of Radiology, Division of Oncology, Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, Calif 94305, USA
    JAMA 295:2374-84. 2006
    ..Screening with contrast-enhanced breast magnetic resonance imaging (MRI) detects cancer earlier but increases costs and results in more false-positive scans...
  14. pmc A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers
    Bronislava M Sigal
    Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Cancer Epidemiol Biomarkers Prev 21:1066-77. 2012
    ..We estimate the impact of different risk-reducing options at various ages on life expectancy...
  15. ncbi Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers
    Ashley D Staton
    Department of Medicine, Stanford University School of Medicine, CCSR Building, Room 1115, 269 Campus Drive, Stanford, CA 94305 5151, USA
    Fam Cancer 7:179-86. 2008
    ..In order to explore women's preferences for management of elevated cancer risk, we evaluated the decisions of BRCA1/2 mutation carriers about contraception, prophylactic surgery, and family planning...
  16. doi Validation of self-reported comorbidity status of breast cancer patients with medical records: the California Breast Cancer Survivorship Consortium (CBCSC)
    Cheryl Vigen
    University of Southern California, 1540 Alcazar St CHP 133, Los Angeles, CA, 90089 9003, USA
    Cancer Causes Control 27:391-401. 2016
    ..To compare information from self-report and electronic medical records for four common comorbidities (diabetes, hypertension, myocardial infarction, and other heart diseases)...
  17. pmc Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Palo Alto, California Department of Health Research and Policy, Stanford University School of Medicine, Palo Alto, California
    Cancer 120:103-11. 2014
    ..In the current study, the authors analyzed the information yielded by integrating breast cancer data from 3 sources: electronic medical records (EMRs) from 2 health care systems and the state registry...
  18. ncbi Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage
    Pejman Ghanouni
    Department of Radiology, Division of Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Breast J 13:281-6. 2007
    ..Knowledge of the potential for breast MRI enhancement subsequent to DL, which can mimic the appearance of a pathologic lesion, is critical to the care of patients who undergo breast MRI and DL or other intraductal cannulation procedures...
  19. doi Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations
    Monique A de Bruin
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Fam Cancer 11:429-39. 2012
    ..Further investigation of racial differences in BRCA1/2 mutation epidemiology could inform targeted cancer risk-reduction strategies...
  20. pmc Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry
    Allison W Kurian
    Stanford University School of Medicine, Department of Health Research and Policy, Stanford, CA 94305 5405, USA
    Cancer Epidemiol Biomarkers Prev 18:1084-91. 2009
    ..Two widely used models, BRCAPRO and BOADICEA, were developed using data from non-Hispanic Whites (NHW), but their accuracies have not been evaluated in other racial/ethnic populations...
  21. pmc Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 29:4505-9. 2011
    ..We estimated breast cancer risks for noncarriers by using a population-based sample of patients with breast cancer and their female first-degree relatives (FDRs)...
  22. pmc Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system
    Theresa H M Keegan
    Theresa H M Keegan, Li Tao, Daphne Y Lichtensztajn, and Scarlett L Gomez are with the Cancer Prevention Institute of California, Fremont Allison W Kurian is with the Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA Kathleen Gali is with the School of Social Sciences, Humanities and Arts, University of California, Merced Dawn L Hershman is with the Columbia University Medical Center, New York, NY Laurel A Habel and Bette J Caan are with the Division of Research, Kaiser Permanente, Oakland, CA
    Am J Public Health 105:938-46. 2015
    ..We examined the combined influence of race/ethnicity and neighborhood socioeconomic status (SES) on short-term survival among women with uniform access to health care and treatment...
  23. ncbi A young woman with bilateral breast cancer: identifying a genetic cause and implications for management
    Monique A de Bruin
    Department of aMedicine, Stanford University School of Medicine, Stanford, California 94305 5405, USA
    J Natl Compr Canc Netw 11:512-7. 2013
    ..Given the specialized counseling and testing needs of patients with Li-Fraumeni syndrome, and the implications for targeted screening strategies if a mutation is found, referral to a cancer genetics expert is strongly recommended...
  24. ncbi The decline in breast cancer incidence: real or imaginary?
    Allison W Kurian
    Stanford University School of Medicine, Stanford, CA 94305, USA
    Curr Oncol Rep 11:21-8. 2009
    ..However, significant controversy remains as to the timing, causes, generalizability, and longevity of this reported decline in incidence...
  25. pmc Intersection of Race/Ethnicity and Socioeconomic Status in Mortality After Breast Cancer
    Salma Shariff-Marco
    Cancer Prevention Institute of California, 2201 Walnut Ave, Suite 300, Fremont, CA, 94538, USA
    J Community Health 40:1287-99. 2015
    ..Considering the joint impacts of these social factors may offer insights to understanding inequalities by multiple social determinants of health...
  26. doi Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, California2Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California
    JAMA 312:902-14. 2014
    ..Bilateral mastectomy is increasingly used to treat unilateral breast cancer. Because it may have medical and psychosocial complications, a better understanding of its use and outcomes is essential to optimizing cancer care...
  27. pmc The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival
    Anna H Wu
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Rm 4443, Los Angeles, CA, 90089, USA
    Cancer Causes Control 24:1821-36. 2013
    ..This cohort will enable analyses to jointly consider a variety of clinical, lifestyle, and contextual factors in attempting to explain the long-standing disparities in breast cancer outcomes...
  28. doi The California breast density information group: a collaborative response to the issues of breast density, breast cancer risk, and breast density notification legislation
    Elissa R Price
    From the Departments of Radiology and Biomedical Imaging, Division of Women s Imaging E R P, E A S, B N J, and Radiology R J B, University of California, San Francisco, San Francisco, Calif Department of Radiology J H, K K L and the Comprehensive Cancer Center D D W, University of California, Davis, Sacramento, Calif Department of Radiology, Stanford University School of Medicine, Advanced Medicine Center, 875 Blake Wilbur Dr, Room CC 2239, Stanford, Calif J A L, D M I Bay Imaging Consultants, Sutter Health, Alta Bates Summitt Medical Center, Carol Ann Read Breast Health Center, Oakland, Calif R J B Department of Radiology, Sutter Health, California Pacific Medical Center, San Francisco, Calif J W T L Department of Radiology, University of California, Irvine Medical Center, Fong and Jean Tsai Professor of Women s Imaging, University of California Irvine School of Medicine, UCI Medical Center, Orange, Calif S A F Department of Radiology, University of California, Los Angeles, Los Angeles, Calif L W B Department of Clinical Radiology, Frankfurt/M
    Radiology 269:887-92. 2013
    ..This multi-institutional, multidisciplinary approach may be useful for organizations to frame responses as similar legislation is passed across the United States. Online supplemental material is available for this article...
  29. pmc Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007
    Allison W Kurian
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 137:247-60. 2013
    ..72, 95 % CI 1.02-2.90). In this equal-access healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors. These findings may inform efforts to optimize quality in breast cancer care...
  30. pmc CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer
    Jeffrey A Norton
    Department of Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94035, USA
    Ann Surg 245:873-9. 2007
    ....
  31. pmc Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
    Melinda L Telli
    Division of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Breast Cancer Res Treat 127:471-8. 2011
    ..Given the poor prognosis and high treatment costs of HER2-positive breast cancer, our results have implications for healthcare resource utilization, cancer biology, and clinical care...
  32. ncbi Rising Bilateral Mastectomy Rates Among Neoadjuvant Chemotherapy Recipients in California From 1998 to 2012
    Irene L Wapnir
    Departments of Surgery, Stanford University School of Medicine, Stanford, CA Departments of Medicine Stanford University School of Medicine, Stanford, CA Departments of Health Research and Policy, Stanford University School of Medicine, Stanford, CA Cancer Prevention Institute of California, Fremont, CA
    Ann Surg . 2016
    ..To study the impact of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) recipients in California...
  33. doi Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population
    Li Tao
    Cancer Prevention Institute of California, Fremont, CA, USA
    Cancer Causes Control 27:1127-38. 2016
    ..To examine the occurrence and outcomes of de novo metastatic (Stage IV) breast cancer, particularly with respect to tumor HER2 expression...
  34. doi A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
    Shaveta Vinayak
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 142:389-98. 2013
    ..The results are inconclusive and do not exclude a favorable effect on breast cancer risk. ..
  35. pmc Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines
    Ashley A Powell
    Department of Surgery, Stanford University School of Medicine, Stanford, California, USA
    PLoS ONE 7:e33788. 2012
    ..Here we demonstrate feasibility of performing high dimensional single CTC profiling, providing early insight into CTC heterogeneity and allowing comparisons to breast cancer cell lines widely used for drug discovery...
  36. ncbi Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988-2013
    Allison W Kurian
    Departments of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Breast Cancer Res Treat 160:333-338. 2016
    ..We evaluated survival after nipple-sparing mastectomy versus non-nipple-sparing mastectomy in a population-based cancer registry...
  37. pmc Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer
    Anosheh Afghahi
    Department of Medicine, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA
    Breast Cancer Res 17:108. 2015
    ..The long-term goal is to enhance standard clinicopathologic measures of low- versus high-risk DCIS and to enable risk-appropriate treatment...
  38. doi Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment
    Allison W Kurian
    aDepartments of Medicine bHealth Research and Policy cPediatrics dGenetics, Stanford University School of Medicine, Stanford, California, USA
    Curr Opin Obstet Gynecol 27:23-33. 2015
    ..To summarize advances in next-generation sequencing and their application to breast and gynecologic cancer risk assessment...
  39. pmc Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research
    Susan C Weber
    Center for Clinical Informatics, Stanford University, USA
    AMIA Annu Symp Proc 2012:970-8. 2012
    ..Through our efforts using these methods, Oncoshare integrates complex, longitudinal data from multiple electronic medical records and registries and provides a rich, validated resource for research on oncology care...
  40. doi Synergistic drug combinations from electronic health records and gene expression
    Yen S Low
    Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA, USA
    J Am Med Inform Assoc . 2016
    ..EHRs provide real-world treatment and outcome patterns, while complementary biomolecular data, including disease-specific gene expression and drug-protein interactions, provide mechanistic understanding...
  41. pmc Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease
    Shaveta Vinayak
    Department of Medicine and Health Research and Policy, Stanford University School of Medicine, HRP Redwood Building, Room T254A, 259 Campus Drive, Stanford, CA 94305, USA
    Curr Breast Cancer Rep 1:148-156. 2009
    ..If results are promising, they may justify a randomized trial of statins for breast cancer chemoprevention, with a focus on HR-negative disease...
  42. pmc Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries
    Ava Kwong
    Department of Surgery, The University of Hong Kong, Hong Kong, Hong Kong Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong, Hong Kong Departments of Medicine Oncology and Genetics, Stanford University School of Medicine, Stanford, California, USA Department of Surgery, Hong Kong Sanatorium and Hospital, Hong Kong, Hong Kong
    J Med Genet 53:15-23. 2016
    ..Understanding BRCA1/BRCA2 mutations in Asians will help provide better risk assessment and clinical management of breast cancer. ..
  43. ncbi Histologic types of epithelial ovarian cancer: have they different risk factors?
    Allison W Kurian
    Department of Medicine, Division of Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305 5820, USA
    Gynecol Oncol 96:520-30. 2005
    ..The goals of the current study were to characterize further the relation of histologic-specific ovarian cancer risks to reproductive and lifestyle attributes...
  44. doi Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology
    Allison W Kurian
    Breast J 14:211-4. 2008
  45. ncbi A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature
    Pavandeep Ghataorhe
    School of Medicine, Oxford University, South Parks Road, Oxford OX1 3PL, UK
    Cancer Genet Cytogenet 179:89-92. 2007
    ..To our knowledge, this is the first report of a patient with both MEN1 and BRCA2 mutations and with a personal history of hyperparathyroidism and pancreatic neuroendocrine tumors...